Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
If a company builds assets at 13.1% a year, faster than its revenue growth rate of 10.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Henan Lingrui Pharmaceutical Co's average Total Assets Growth Rate was 7.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 19.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 13.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 5.60% per year.
During the past 13 years, Henan Lingrui Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 44.20%. The lowest was -3.20%. And the median was 9.30%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Henan Lingrui Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Henan Lingrui Pharmaceutical Co Total Assets Related Terms
Henan Lingrui Pharmaceutical Co Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co Total Assets Chart
Henan Lingrui Pharmaceutical Co Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a Total Assets of ¥5,966 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Henan Lingrui Pharmaceutical Co and its competitors.
Is Henan Lingrui Pharmaceutical Co's Total Assets too high?
Henan Lingrui Pharmaceutical Co's current Total Assets is ¥5,966 Mil. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's Total Assets compare to ZTS and UTHR?
Henan Lingrui Pharmaceutical Co's Total Assets of ¥5,966 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. Henan Lingrui Pharmaceutical Co's current Total Assets is ¥5,966 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Fairly Valued. The stock's GF Value™ is ¥24.40, compared to a current price of ¥22.92 — trading 6.1% below its estimated fair value. The current Total Assets is ¥5,966 Mil. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current Total Assets is ¥5,966 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥22.92 is trading 6.1% below its estimated GF Value™ of ¥24.40.
GuruFocus considers Henan Lingrui Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600285:
Total Assets: ¥5,966 Mil
GF Value™: ¥24.40 vs. price of ¥22.92 (6.1% below fair value)
No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Lingrui Pharmaceutical Co Business Description
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
94GF Score
Get the complete analysis for SHSE:600285
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600285 has been successfully added to your 
